[A21-65] Obinutuzumab (follicular lymphoma, after rituximab) - Benefit assessment according to §35a Social Code Book V
Last updated 16.08.2021
Commission awarded on 12.05.2021 by the Federal Joint Committee (G-BA).
Adults with follicular lymphoma who did not respond to treatment with rituximab alone or in combination with other drugs, or whose disease has progressed during or up to 6 months after treatment with rituximab
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|G17-11||Obinutuzumab (non-pretreated advanced follicular lymphoma) - Assessment according to §35a (1), Sentence 11, Social Code Book V||Commission completed|
|G16-07||Obinutuzumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V||Commission completed|
|G14-08||Obinituzumab - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)||Commission completed|
|A21-64||Obinutuzumab (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A21-66||Obinutuzumab (follicular lymphoma, first line) - Benefit assessment according to §35a Social Code Book V||Commission completed|